Trial Profile
Systematic Profiling of Anti-inflammatory Drugs for the Detection of Drug- Specific Response Signatures in the Treatment of Chronic Inflammatory Disorders
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary) ; Infliximab
- Indications Inflammatory bowel diseases
- Focus Therapeutic Use
- Acronyms Phen_IBD
- 30 Jun 2022 Status changed from recruiting to completed.
- 15 May 2018 New trial record
- 05 May 2018 Results assessing association of vedolizumab and mucosal and systemic immunity (n= 38) published in the Gut.